Get started
111

ICURE PHARMACEUTICAL INCORPORATION

No trades
See on Supercharts
Overview
Financials Discussions Technicals Seasonals

175250 chart


Full chart

Key stats


Market capitalization
‪79.41 B‬ KRW
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−635 KRW
Net income (FY)
‪−31.42 B‬ KRW
Revenue (FY)
‪56.81 B‬ KRW
Shares float
‪31.53 M‬
Beta (1Y)
−0.50

Employees


Employees (FY)
280
Change (1Y)
+5 +1.82%
Revenue / Employee (1Y)
‪155.81 K‬ KRW
Net income / Employee (1Y)
‪−86.18 K‬ KRW

About ICURE PHARMACEUTICAL INCORPORATION


Sector
Health Technology
CEO
Choi Young
Headquarters
Seoul
Website
icure.co.kr
Founded
2000
ISIN
KR7175250000
FIGI
BBG00L1561Q3
Icure Pharmaceutical Inc. engages in the development and manufacture of transdermal drug delivery system. It operates through the pharmaceutical and cosmeceutical business. The pharmaceutical business provides specialized and over-the-counter medical products such as anesthetic drugs, anticonvulsant, mixed vitamin pills, fever reducer, anti-inflammatory drugs, painkiller and others. The cosmeceutical business offers skin care, hair care and body products such as skin lotion, cream, cleanser, shampoo, hair essence, hand cream, mask and others. The company was founded on May 29, 2000 and is headquartered in Seoul, South Korea.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 175250 is 2,025 KRW — it has decreased by −6.70% in the past 24 hours. Watch ICURE PHARMACEUTICAL INCORPORATION stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange ICURE PHARMACEUTICAL INCORPORATION stocks are traded under the ticker 175250.
175250 stock has fallen by −11.01% compared to the previous week, the month change is a 1.46% rise, over the last year ICURE PHARMACEUTICAL INCORPORATION has showed a 7.37% increase.
175250 reached its all-time high on Feb 16, 2021 with the price of 24,625 KRW, and its all-time low was 1,775 KRW and was reached on Oct 23, 2023. View more price dynamics on 175250 chart.
See other stocks reaching their highest and lowest prices.
175250 stock is 4.10% volatile and has beta coefficient of −0.50. Track ICURE PHARMACEUTICAL INCORPORATION stock price on the chart and check out the list of the most volatile stocks — is ICURE PHARMACEUTICAL INCORPORATION there?
Today ICURE PHARMACEUTICAL INCORPORATION has the market capitalization of ‪80.91 B‬, it has decreased by −6.37% over the last week.
Yes, you can track ICURE PHARMACEUTICAL INCORPORATION financials in yearly and quarterly reports right on TradingView.
175250 net income for the last quarter is ‪−486.12 M‬ KRW, while the quarter before that showed ‪−4.67 B‬ KRW of net income which accounts for 89.58% change. Track more ICURE PHARMACEUTICAL INCORPORATION financial stats to get the full picture.
No, 175250 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 13, 2024, the company has 280.00 employees. See our rating of the largest employees — is ICURE PHARMACEUTICAL INCORPORATION on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ICURE PHARMACEUTICAL INCORPORATION EBITDA is ‪−15.89 B‬ KRW, and current EBITDA margin is −32.89%. See more stats in ICURE PHARMACEUTICAL INCORPORATION financial statements.
Like other stocks, 175250 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ICURE PHARMACEUTICAL INCORPORATION stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ICURE PHARMACEUTICAL INCORPORATION technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ICURE PHARMACEUTICAL INCORPORATION stock shows the sell signal. See more of ICURE PHARMACEUTICAL INCORPORATION technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.